broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K36788280-001-01-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.444549 | -0.801651 | 0.131174 | 0.926624 | 0.001267 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-001145 |
BRD-K37379014-001-02-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.135823 | 4.085562 | 0.68761 | 0.751825 | 0.009612 | 0.010387 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001145 |
BRD-K38332599-001-01-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.164099 | 2.696736 | 0.618733 | 0.817674 | 1.20569 | 1.397348 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-001145 |
BRD-K38527262-300-01-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.029031 | 1.039078 | 0.447599 | 0.810155 | 1.59424 | 1.688732 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-001145 |
BRD-K38852836-001-02-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.297457 | 5.180122 | 0.816209 | 0.636362 | 0.016487 | 0.01963 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001145 |
BRD-K39974922-001-04-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.455283 | -0.288638 | -0.207852 | 1 | 0.022008 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-001145 |
BRD-K41859756-001-06-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.280515 | 6.292105 | 0.736819 | 0.513987 | 0.003564 | 0.004062 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001145 |
BRD-K42495768-001-01-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.069064 | -0.060116 | -0.058585 | 1 | 1.628735 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-001145 |
BRD-K42805893-001-04-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.259412 | 3.058995 | 0.535131 | 0.874428 | 1.933313 | 2.455623 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-001145 |
BRD-K42828737-001-03-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | -0.135178 | 3.663084 | 0.296266 | 0.953453 | 7.22099 | 6.764202 | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-001145 |
BRD-K42898655-001-01-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.812272 | 2.047393 | 0.248991 | 0.877005 | 0.001082 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001145 |
BRD-K43389675-001-02-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.096384 | 2.958044 | 0.836261 | 0.392357 | 0.014649 | 0.015749 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-001145 |
BRD-K44227013-001-06-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.187073 | 2.43161 | 0.522156 | 0.824219 | 1.22953 | 1.49087 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-001145 |
BRD-K44408410-001-17-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | -0.181868 | 3.434148 | 0.492283 | 0.95893 | 7.965491 | 7.277436 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-001145 |
BRD-K44827188-001-06-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.806265 | 2.849405 | 0.386298 | 1 | 6.017351 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-001145 |
BRD-K46386702-001-02-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.817313 | 0.004427 | -0.005207 | 0.908256 | 0.010787 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-001145 |
BRD-K49328571-001-15-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.28788 | 1.520752 | 0.734265 | 0.532437 | 0.01702 | 0.02991 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-001145 |
BRD-K49350383-001-14-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.353592 | 0.082929 | -0.020159 | 1 | 4.857031 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-001145 |
BRD-K50010139-001-01-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.847303 | -0.152345 | -0.042929 | 0.928644 | 0.031802 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-001145 |
BRD-K50168500-001-07-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.769598 | 0.814644 | -0.045206 | 0.897527 | 0.136432 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-001145 |
BRD-K51313569-001-07-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.324989 | 4.106613 | 0.485615 | 0.909902 | 2.741343 | 3.539777 | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-001145 |
BRD-K51791723-003-01-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | -0.082453 | 0.419306 | 0.471946 | 0.514238 | 0.149378 | 0.103798 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001145 |
BRD-K51967704-001-03-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.269543 | 0.496205 | 0.59888 | 0.622185 | 0.063923 | 0.304482 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001145 |
BRD-K52313696-001-12-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.555287 | 3.739171 | 0.63588 | 1 | 0.744782 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001145 |
BRD-K53414658-001-08-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.165543 | -1.616161 | 0.016703 | 1 | 1.686713 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-001145 |
BRD-K53972329-001-07-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.002465 | -0.22686 | -0.035244 | 1 | 0.033759 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-001145 |
BRD-K54256913-001-08-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.821273 | -6.874879 | -0.02909 | 0.886637 | 0.287472 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-001145 |
BRD-K54955827-001-02-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.560465 | 1.224493 | 0.348332 | 0.900835 | 1.18643 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-001145 |
BRD-K54997624-001-06-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.147975 | -0.181586 | -0.038793 | 1 | 0.225408 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-001145 |
BRD-K55187425-236-05-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.209709 | 1.269999 | 0.827573 | 0.537236 | 0.033902 | 0.052019 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-001145 |
BRD-K56343971-001-14-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.948576 | -5.997882 | -0.228465 | 0.967373 | 0.287983 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-001145 |
BRD-K56981171-001-02-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.098507 | 0.006164 | -0.014347 | 1 | 3,134,718,907,065,312,000,000 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-001145 |
BRD-K57080016-001-15-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.843757 | 6.617543 | 0.125826 | 0.921355 | 0.075604 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-001145 |
BRD-K57169635-001-04-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.041909 | 1.063456 | 0.481768 | 0.844527 | 2.516073 | 2.731924 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-001145 |
BRD-K58435339-001-03-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.270833 | 4.256102 | 0.811527 | 0.61221 | 0.057349 | 0.068887 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-001145 |
BRD-K58529924-001-01-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.060061 | -0.332889 | -0.009676 | 1 | 4.249343 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-001145 |
BRD-K58550667-001-08-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.134919 | 3.818674 | 0.7864 | 0.762669 | 0.043605 | 0.047348 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-001145 |
BRD-K59317601-001-05-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.239667 | 0.756203 | 0.686447 | 0.587481 | 0.050556 | 0.119839 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-001145 |
BRD-K59369769-001-22-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.670768 | 9.539331 | 0.367093 | 0.835231 | 0.077751 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-001145 |
BRD-K60866521-001-07-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.013357 | -0.173534 | -0.005179 | 1 | 4.357483 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-001145 |
BRD-K60997853-001-02-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.066323 | 3.854224 | 0.605014 | 0.851925 | 2.147249 | 2.228017 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-001145 |
BRD-K61192372-001-08-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.76315 | -0.509535 | -0.058917 | 0.871007 | 0.130542 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-001145 |
BRD-K62008436-001-23-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.082181 | 0.802493 | 0.792215 | 0.474372 | 0.002336 | 0.002922 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-001145 |
BRD-K62196610-001-01-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.911506 | -0.196512 | 0.032187 | 0.947294 | 0.647512 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-001145 |
BRD-K62200014-003-10-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.292529 | 0.323077 | 0.000075 | 1 | 0.620918 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-001145 |
BRD-K62391742-001-09-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.959971 | 2.231618 | 0.497578 | 1 | 4.175612 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-001145 |
BRD-K62627508-001-01-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.317155 | 0.441214 | -0.013959 | 1 | 0.261712 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-001145 |
BRD-K63504947-001-14-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.084982 | -0.543708 | -0.058028 | 1 | 0.115253 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-001145 |
BRD-K63712959-001-01-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.386951 | 0.184202 | 0.090078 | 1 | 2.886445 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-001145 |
BRD-K64052750-001-22-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.952545 | 0.113502 | -0.076571 | 0.966417 | 0.000027 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-001145 |
BRD-K64881305-001-03-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.147583 | 5.656251 | 0.863902 | 0.470761 | 0.024168 | 0.02571 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-001145 |
BRD-K66175015-001-12-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.158737 | 1.80721 | 0.633062 | 0.709277 | 0.349991 | 0.432362 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-001145 |
BRD-K67844266-003-01-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.317313 | 2.169354 | 0.338657 | 0.730024 | 0.215434 | 0.342671 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-001145 |
BRD-K69001009-001-02-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.84953 | 1.309648 | 0.052335 | 0.903248 | 0.019342 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-001145 |
BRD-K69694239-001-02-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.135839 | 9.003081 | 0.764339 | 0.778997 | 0.835846 | 0.865796 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-001145 |
BRD-K69776681-001-03-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.162309 | 3.998753 | 0.819744 | 0.501401 | 0.031003 | 0.0342 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-001145 |
BRD-K70301465-001-05-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.883937 | 0.445636 | 0.044797 | 0.976023 | 4.07587 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-001145 |
BRD-K70401845-001-15-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.103562 | -0.002004 | -0.000876 | 1 | 4,199,339,110,032,357,000,000,000,000 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-001145 |
BRD-K73838513-003-05-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.971053 | 0.052603 | -0.00252 | 0.982512 | 0.000024 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-001145 |
BRD-K74514084-003-09-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.906568 | -0.013602 | -0.010899 | 0.947633 | 4,539,330.818583 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-001145 |
BRD-K75009076-001-02-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.015622 | -0.618441 | -0.022405 | 1 | 0.000202 | null | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-001145 |
BRD-K76210423-001-01-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.760785 | -0.307376 | -0.107386 | 0.849798 | 0.576642 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-001145 |
BRD-K76239644-001-02-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.164121 | 0.883709 | 0.668303 | 0.79083 | 1.01309 | 1.589181 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-001145 |
BRD-K76674262-001-03-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.142572 | 6.000997 | 0.599699 | 0.728058 | 0.460547 | 0.487049 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-001145 |
BRD-K76908866-001-07-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.065716 | 0.175953 | -0.005128 | 1 | 0.021096 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-001145 |
BRD-K77625799-001-07-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.398748 | 0.800382 | 0.332653 | 0.812934 | 0.545539 | 4.012098 | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-001145 |
BRD-K78431006-001-15-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.591151 | -2.589683 | 0.064538 | 0.971025 | 0.00113 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-001145 |
BRD-K79254416-001-21-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.644076 | 1.060767 | 0.268953 | 0.856253 | 0.201091 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-001145 |
BRD-K81016934-001-02-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.78997 | 0.175818 | 0.025418 | 0.878646 | 0.011794 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-001145 |
BRD-K81473043-001-19-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.27361 | 5.931941 | 0.64803 | 0.83813 | 0.071881 | 0.082153 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001145 |
BRD-K82135108-001-04-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.991406 | 2.200948 | 0.272906 | 1 | 0.013412 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-001145 |
BRD-K82746043-001-19-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.779191 | 0.217633 | 0.079959 | 1 | 0.971662 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-001145 |
BRD-K82818427-001-04-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.745276 | 3.495599 | 0.140216 | 0.892654 | 0.167437 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001145 |
BRD-K83029223-001-01-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.09691 | 9.033523 | 0.830759 | 0.587144 | 0.007396 | 0.007574 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001145 |
BRD-K83988098-001-02-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.170496 | 6.90201 | 0.72869 | 0.786031 | 0.012765 | 0.01356 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001145 |
BRD-K85402309-043-01-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.084587 | 4.968615 | 0.450497 | 0.86264 | 2.33152 | 2.420129 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-001145 |
BRD-K85606544-001-09-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.617799 | 3.216088 | 0.354007 | 0.84834 | 0.212613 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001145 |
BRD-K86118762-001-01-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.29588 | -0.155581 | -0.010179 | 1 | 0.011581 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-001145 |
BRD-K86972824-001-01-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.042224 | 0.060107 | -0.003938 | 1 | 0.00041 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001145 |
BRD-K87737963-001-06-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.058112 | 2.490065 | 0.59227 | 0.90471 | 3.885361 | 4.083008 | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-001145 |
BRD-K87782578-001-01-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.388393 | 3.936758 | 0.359427 | 0.931751 | 3.398211 | 4.973749 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-001145 |
BRD-K87909389-003-03-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.199835 | 3.000995 | 0.842419 | 0.542647 | 0.038995 | 0.046222 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001145 |
BRD-K88510285-001-17-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.210327 | 7.752309 | 0.853608 | 0.633637 | 0.027748 | 0.029772 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001145 |
BRD-K89014967-001-04-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.576364 | -0.007133 | -0.000097 | 0.793277 | 0.000092 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001145 |
BRD-K92441787-001-04-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.787699 | -0.571987 | 0.10582 | 0.934414 | 0.00898 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001145 |
BRD-K92723993-001-17-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.12193 | -0.260147 | 0.010569 | 1 | 0.000176 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-001145 |
BRD-K95142244-001-01-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.13974 | 1.492041 | 0.750023 | 0.727236 | 0.464086 | 0.578106 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001145 |
BRD-K96123349-236-02-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.884441 | 0.936375 | -0.034996 | 0.979397 | 2.241679 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-001145 |
BRD-K98572433-001-02-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.747228 | 0.565485 | 0.080292 | 0.886559 | 0.137612 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-001145 |
BRD-K99113996-001-02-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.266485 | 1.252258 | 0.697566 | 0.813841 | 0.884234 | 1.624101 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-001145 |
BRD-K99616396-001-05-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.932085 | -0.287904 | -0.039139 | 0.957429 | 0.624339 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001145 |
BRD-K99749624-001-07-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.333721 | 0.434515 | 0.103049 | 1 | 2.564449 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-001145 |
BRD-M97302542-001-04-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.992582 | 0.212977 | -0.011362 | 0.996181 | 0.057745 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-001145 |
BRD-A25234499-001-19-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.038414 | 0.029157 | -0.004075 | 1 | 0.000136 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-001190 |
BRD-A70858459-001-01-7 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.881273 | -4.724437 | 0.205851 | 0.938348 | 0.094165 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-001190 |
BRD-A74914197-001-02-9 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.309163 | 1.21931 | 0.437341 | 0.756023 | 0.020542 | 0.04526 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001190 |
BRD-K02113016-001-19-6 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.416769 | -0.992146 | 0.081964 | 0.962398 | 0.000524 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001190 |
BRD-K02130563-001-11-4 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.098444 | 0.871255 | 0.835971 | 0.427373 | 0.020046 | 0.025782 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001190 |
BRD-K03390685-001-01-7 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.270527 | 2.778669 | 0.751787 | 0.768084 | 0.457185 | 0.605091 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001190 |
BRD-K03406345-001-21-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.184133 | 0.269152 | -0.060281 | 0.905628 | 325.578297 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001190 |
Subsets and Splits